These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36652465)

  • 21. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial.
    Zhang XD; Gu J; Jiang WF; Zhao L; Zhou L; Wang YL; Liu YG; Liu X
    Eur Heart J; 2014 May; 35(20):1327-34. PubMed ID: 24497338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.
    Kishima H; Mine T; Fukuhara E; Kitagaki R; Asakura M; Ishihara M
    JACC Clin Electrophysiol; 2022 Nov; 8(11):1393-1404. PubMed ID: 36424008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data.
    Chen S; Pürerfellner H; Meyer C; Acou WJ; Schratter A; Ling Z; Liu S; Yin Y; Martinek M; Kiuchi MG; Schmidt B; Chun KRJ
    Eur Heart J; 2020 Aug; 41(30):2863-2873. PubMed ID: 31298266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).
    Hunter RJ; Berriman TJ; Diab I; Kamdar R; Richmond L; Baker V; Goromonzi F; Sawhney V; Duncan E; Page SP; Ullah W; Unsworth B; Mayet J; Dhinoja M; Earley MJ; Sporton S; Schilling RJ
    Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):31-8. PubMed ID: 24382410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Maintenance of Sinus Rhythm of Value in Patients with Atrial Fibrillation and Heart Failure?
    Sadek MM; Skanes A; Tang ASL
    Curr Cardiol Rep; 2022 Oct; 24(10):1227-1231. PubMed ID: 35870075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acupuncture for persistent atrial fibrillation after catheter ablation: study protocol for a pilot randomized controlled trial.
    Lin Y; Wang X; Li XB; Wu BQ; Zhang ZH; Guo WH; Wu CC; Chen X; Chen ML; Dai Z; Chen FY; Zhu R; Liang CX; Tian YP; Yang G; Yan CQ; Lu J; Wang HY; Li JL; Tu JF; Li HW; Yang DD; Yu FT; Wang Y; Yang JW; Shi GX; Yan SY; Wang LQ; Liu CZ
    Trials; 2021 Jan; 22(1):35. PubMed ID: 33413569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
    Ong HT; Teo YH; Teo YN; Syn NL; Wee CF; Leong S; Yip ASY; See RM; Ting AZH; Chia AZ; Cheong AJY; Tan BY; Ho JS; Yeo LL; Leow AS; Yeo TC; Wong RC; Chai P; Kojodjojo P; Sia CH
    J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106159. PubMed ID: 34689051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.
    Vrachatis DA; Papathanasiou KA; Iliodromitis KE; Giotaki SG; Kossyvakis C; Raisakis K; Kaoukis A; Lambadiari V; Avramides D; Reimers B; Stefanini GG; Cleman M; Giannopoulos G; Lansky A; Deftereos SG
    Drugs; 2021 Aug; 81(12):1381-1395. PubMed ID: 34297330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation: Substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) Randomized Clinical Trial.
    Samuel M; Khairy P; Champagne J; Deyell MW; Macle L; Leong-Sit P; Novak P; Badra-Verdu M; Sapp J; Tardif JC; Andrade JG
    JAMA Cardiol; 2021 Nov; 6(11):1324-1328. PubMed ID: 34406350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.
    Am Heart J; 2002 Oct; 144(4):597-607. PubMed ID: 12360154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atrial Fibrillation Burden and Clinical Outcomes in Heart Failure: The CASTLE-AF Trial.
    Brachmann J; Sohns C; Andresen D; Siebels J; Sehner S; Boersma L; Merkely B; Pokushalov E; Sanders P; Schunkert H; Bänsch D; Dagher L; Zhao Y; Mahnkopf C; Wegscheider K; Marrouche NF
    JACC Clin Electrophysiol; 2021 May; 7(5):594-603. PubMed ID: 33640355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?
    Mishriky BM; Cummings DM; Powell JR
    Diabetes Metab Res Rev; 2024 Jan; 40(1):e3715. PubMed ID: 37649368
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan-Meier Curves with Trial Sequential Analysis.
    Soliman Y; Abuelazm M; Amer BE; Hukamdad M; Ellabban MH; Hendi NI; Mouffokes A; AbdelAzeem B; Hassaballa H
    Am J Cardiovasc Drugs; 2024 Sep; 24(5):629-640. PubMed ID: 38963527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?
    Matta M; Saglietto A; De Salvo P; Bissolino A; Ballatore A; Anselmino M
    Herz; 2019 May; 44(3):218-222. PubMed ID: 30847508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.